Hear from Wes LaBarge as he introduces MedPharm’s Olink® capabilities and discusses how targeted multiplex proteomic analysis can generate deeper insights from samples to support drug development.

The high attrition rate in drug development, driven by factors like poor efficacy, safety, and developability, requires a strategic, early-stage approach to minimize risk and cost. Success depends on a robust development strategy and comprehensive characterization aligned with quality standards. Key Learning Objectives Define the principles of topical formulation development and its role in drug […]

Developing a semi-solid topical drug product demands a deeper level of scientific and process understanding than traditional solid dosage forms. Every choice, from excipient interactions to the order of ingredient addition, shapes the product’s microstructure, physical stability, and patient experience. Because subtle processing shifts can alter drug release, texture, and long-term uniformity, early formulation decisions […]